Abstract
The ABC transporters represent the largest family of transmembrane proteins. They also serve in protective roles whereby many transporters act as efflux pumps for xenobiotics. And subsequently, several members; most notably of the A, B and C subfamilies, have been implicated in cancer chemoresistance; however, D family members have not been extensively studies with regards to cancer biology and treatment. Here we report that ABCD3 transporter expression is upregulated in breast cancer (p<0.001). The gene was also upregulated across cancer stages (p<0.05). Analysis of histological subtypes revealed that ABCD3 was expressed infiltrating ductal carcinoma (IDC). Immunohistochemistry (IHC) analysis confirmed that ABCD3 protein is expressed IDC (p<0.001). Moreover, ABCD3 expression was elevated in White (p<0.001) and Asian (p<0.05) breast cancer patients but not in African-American patients. Analysis of molecular subtypes revealed that ABCD3 expression was significantly higher in the Luminal breast cancer subtype (p<0.001). Furthermore, ROC analysis of gene expression in relationship in response to treatment revealed that ABCD3 is a moderate predictor (AUC=0.644, p=0.003) of response to endocrine therapy (tamoxifen and aromatase inhibitors) and a strong predictor (AUC=08, p=0.026) to chemotherapy in luminal breast cancers. Taken collectively, ABCD3 represents a biomarker which may be important for determining therapeutic response.
Citation Format: Romonia Renee Reams, Simone Heyliger, Marilyn Saulsbury. ABCD3 expression is upregulated Caucasian and Asian breast cancer patients and is associated with non-responsiveness to endocrine therapy in luminal breast cancers [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C031.
RSS Feeds